0.70
Salarius Pharmaceuticals Inc stock is traded at $0.70, with a volume of 24,667.
It is down -1.44% in the last 24 hours and down -33.33% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$0.7102
Open:
$0.6814
24h Volume:
24,667
Relative Volume:
0.02
Market Cap:
$1.49M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
-0.109
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
+11.09%
1M Performance:
-33.33%
6M Performance:
-74.36%
1Y Performance:
-73.18%
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare SLRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SLRX
Salarius Pharmaceuticals Inc
|
0.70 | 1.51M | 4.70M | -4.99M | -5.29M | -6.42 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
Is Salarius Pharmaceuticals Inc. a good long term investmentFree Stock Chart Pattern Guide - Autocar Professional
What analysts say about Salarius Pharmaceuticals Inc. stockHigh-yield investments - jammulinksnews.com
What drives Salarius Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange - Investing.com
Salarius Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough stock performance - printweek.in
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% – What’s Next? - Defense World
How Salarius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Return Analysis - Newser
Why Salarius Pharmaceuticals Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
What makes Salarius Pharmaceuticals Inc. stock price move sharplyShort Squeeze Radar - Newser
Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance - MSN
Salarius Pharmaceuticals Granted Extension to Regain Compliance With Nasdaq's Stockholders' Equity Requirement - MarketScreener
Salarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy Therapeutics - Quiver Quantitative
SLRX gets Nasdaq extension; equity deadline moves to late-July 2025 | NDSN SEC FilingForm 8-K - Stock Titan
Salarius Pharmaceuticals Granted Additional Extension to - GlobeNewswire
Salarius Secures Critical Nasdaq Extension Amid $2.5M Equity Requirement Challenge - Stock Titan
Salarius Pharmaceuticals’ Seclidemstat Demonstrates - GlobeNewswire
Salarius Pharmaceuticals, Inc. Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - MarketScreener
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewswire
Breakthrough Studies Support Salarius Cancer Drug Effectiveness While Clinical Trials Show Promise - Stock Titan
Salarius Pharmaceuticals reports progress in LSD1 inhibitor study, merger with Decoy Therapeutics. - AInvest
Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance - Investing.com Nigeria
Salarius Pharmaceuticals Approves Reverse Stock Split - TipRanks
Why Is Salarius Pharmaceuticals Stock (SLRX) Up 110% Today? - The Globe and Mail
Salarius Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SLRX - Benzinga
What's Going On With Salarius Pharmaceuticals Shares Today? - Benzinga
Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards - Nasdaq
Why Lennar Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Salarius Pharmaceuticals Granted Nasdaq Compliance Extension - TipRanks
Salarius Pharmaceuticals adjusts merger terms amid market shifts By Investing.com - Investing.com Nigeria
Salarius Pharmaceuticals adjusts merger terms amid market shifts - Investing.com Australia
Salarius Pharmaceuticals Enters Second Amendment To Merger Agreement With DecoySEC Filing - MarketScreener
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):